Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Silencing of COX-2 by RNAi Modulates Epithelial-Mesenchymal Transition in Breast Cancer Cells Partially Dependent on the PGE2 Cascade

  • Cao, Juan (Department of Health Care, Weifang Medical University) ;
  • Yang, Xiao (Nursing School, Weifang Medical University) ;
  • Li, Wen-Tong (Department of Pathology, Weifang Medical University) ;
  • Zhao, Chun-Ling (Department of Biology, Weifang Medical University) ;
  • Lv, Shi-Jun (Department of Pathology, Weifang Medical University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

In order to prove whether downregulation of COX-2 (Cyclooxygenase-2) could modulate the epithelial-mesenchymal transition (EMT) of breast cancer, celecoxib and siRNA were respectively used to inhibit COX-2 function and expression in MDA-MB-231 cells. The EMT reversal effect in the RNAi treated group was better than that of the celecoxib group while there were no obvious differences in the medium $PGE_2$ levels between the two groups. The results show that COX-2 pathways may contribute considerably to EMT of breast cancer cells, partially dependent on the PGE2 cascade. Akt2, ZEB2 and Snail were measured to clarify the underlying mechanisms of COX-2 on EMT; COX-2 may modulate EMT of breast cancer by regulating these factors. This finding may be helpful to elucidate the mechanisms of selective COX-2 inhibitor action in EMT modulation in breast cancer.

Keywords

References

  1. Ansieau S (2013). EMT in breast cancer stem cell generation. Cancer Lett, 338, 63-8. https://doi.org/10.1016/j.canlet.2012.05.014
  2. Arboleda MJ, Lyons JF, Kabbinavar FF, et al (2003). Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res, 63, 196-206.
  3. Bellacosa A, Testa JR, Moore R, Larue, L (2004). A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther, 3, 268-75. https://doi.org/10.4161/cbt.3.3.703
  4. Bocca C, Bozzo F, Bassignana A, Miglietta A (2011). Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem, 350, 59-70. https://doi.org/10.1007/s11010-010-0682-4
  5. Cheng J, Fan XM (2013). Role of cyclooxygenase-2 in gastric cancer development and progression. World J Gastroenterol, 19, 7361-8. https://doi.org/10.3748/wjg.v19.i42.7361
  6. Dohadwala M, Yang SC, Luo J, et al (2006). Cyclooxygenase- 2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in nonsmall cell lung cancer. Cancer Res, 66, 5338-45. https://doi.org/10.1158/0008-5472.CAN-05-3635
  7. Falandry C, Canney PA, Freyer G, Dirix LY (2009). Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol, 20, 615-20. https://doi.org/10.1093/annonc/mdn693
  8. Gonzalez-Villasana V, Gutierrez-Puente Y, Tari AM (2013). Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells. Oncol Rep, 30, 1506-10.
  9. Harris RE (2007). Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem, 42, 93-126. https://doi.org/10.1007/1-4020-5688-5_4
  10. Harris RE (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17, 55-67. https://doi.org/10.1007/s10787-009-8049-8
  11. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 4, 988-1004. https://doi.org/10.1038/nrd1902
  12. Hoellen F, Kelling K, Dittmer C, et al (2011). Impact of cyclooxygenase-2 in breast cancer. Anticancer Res, 31, 4359-67.
  13. Huber MA, Kraut N, Beug H (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol, 17, 548-58. https://doi.org/10.1016/j.ceb.2005.08.001
  14. Jendrossek V (2013). Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett, 332, 313-24. https://doi.org/10.1016/j.canlet.2011.01.012
  15. Kalluri R, Weinberg RA (2009). The basics of epithelialmesenchymal transition. J Clin Invest, 119, 1420-8. https://doi.org/10.1172/JCI39104
  16. Ksiazkiewicz M, Markiewicz A, Zaczek AJ (2012). Epithelialmesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology, 79, 195-208. https://doi.org/10.1159/000337106
  17. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y (2009). Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer cell, 15, 195-206. https://doi.org/10.1016/j.ccr.2009.01.023
  18. Kulkarni S, Patil DB, Diaz LK, et al (2008). COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer, 8, 36. https://doi.org/10.1186/1471-2407-8-36
  19. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL (2007). uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol, 178, 425-36. https://doi.org/10.1083/jcb.200701092
  20. Li Q, Mattingly RR (2008). Restoration of E-cadherin cellcell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Rastransformed breast epithelial cells. Neoplasia, 10, 1444-58. https://doi.org/10.1593/neo.08968
  21. Li W, Liu C, Tang Y, Li H, Zhou F, Lv S (2011). Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells. Asian Pac J Cancer Prev, 12, 2575-80.
  22. Moody SE, Perez D, Pan TC, et al (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell, 8, 197-209. https://doi.org/10.1016/j.ccr.2005.07.009
  23. Nam EH, Lee Y, Park YK, Lee JW, Kim S (2012). ZEB2 upregulates integrin alpha5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis, 33, 563-71. https://doi.org/10.1093/carcin/bgs005
  24. Ogunwobi OO, Wang T, Zhang L, Liu C (2012). Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelialmesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol, 27, 566-78. https://doi.org/10.1111/j.1440-1746.2011.06980.x
  25. Park JW, Park JE, Lee JA, Lee CW, Kim CM (2006). Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol, 132, 184-92. https://doi.org/10.1007/s00432-005-0060-x
  26. Patel AR, Chougule MB, Patlolla R, Wang G, Singh M (2013). Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res, 30, 1435-46. https://doi.org/10.1007/s11095-013-0984-9
  27. Roxanis I (2013). Occurrence and significance of epithelialmesenchymal transition in breast cancer. J Clin Pathol, 66, 517-21. https://doi.org/10.1136/jclinpath-2012-201348
  28. Sooriakumaran P, Coley HM, Fox SB, et al (2009). A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res, 29, 1483-8.
  29. Thiel A, Mrena J, Ristimaki A (2011). Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev, 30, 387-95. https://doi.org/10.1007/s10555-011-9312-1
  30. Thompson EW, Newgreen DF, Tarin D (2005). Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res, 65, 5991-5; discussion 5995.
  31. Vandesompele J, De Preter K, Pattyn F, et al (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol, 3, 34.
  32. Wang WS, Yu SL, Yang XS, Chang SD, Hou JQ (2013). Expression and significance of twist and E-cadherin in ovarian cancer tissues. Asian Pac J Cancer Prev, 14, 669-72. https://doi.org/10.7314/APJCP.2013.14.2.669
  33. Williams CS, Mann M, DuBois RN (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18, 7908-16.
  34. Xin X, Majumder M, Girish GV, et al (2012). Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest, 92, 1115-28. https://doi.org/10.1038/labinvest.2012.90
  35. Zhu QC, Gao RY, Wu W, Qin HL (2013). Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian PacJ Cancer Prev, 14, 2689-98. https://doi.org/10.7314/APJCP.2013.14.5.2689

Cited by

  1. Hypermethylation of TET1 Promoter Is a New Diagnosic Marker for Breast Cancer Metastasis vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1197
  2. Prostaglandin E2 promotes human cholangiocarcinoma cell proliferation, migration and invasion through the upregulation of β-catenin expression via EP3-4 receptor vol.34, pp.2, 2015, https://doi.org/10.3892/or.2015.4043